Home › Funds › NEXTBio Capital Management LP › STTK

NEXTBio Capital Management LP position in STTK

SHATTUCK LABS INC · Health Care

NEXTBio Capital Management LP reported holding 3,727,348 shares of STTK (SHATTUCK LABS INC) in its Q3 2026 13F filing — a position valued at US$25.4M, representing 11.07% of its reported portfolio and ranking #2 among its reported holdings. NEXTBio Capital Management LP has disclosed STTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)3.73M sh
Reported value held$25.42M
Portfolio Weight11.07%
First reportedQ4 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How NEXTBio Capital Management LP's STTK position evolved

NEXTBio Capital Management LP first disclosed a stake in STTK in Q4 2025 at 3,149,907 shares (US$11.5M). The position peaked in Q2 2026 at 3,727,348 shares, worth US$25.9M. Across 4 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 3,727,348 shares valued at US$25.4M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 3.15M $11.50M New
Q1 2026 3.15M $20.25M Hold
Q2 2026 3.73M $25.87M Add
Q3 2026 3.73M $25.42M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About STTK and 13F data

STTK (SHATTUCK LABS INC) is a Health Care company. 59 other funds we track also report a position in STTK — the largest reported positions include Redmile Group, LLC (US$47.8M), ORBIMED ADVISORS LLC (US$43.8M), Prosight Management, LP (US$41.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding STTK

All STTK fund holders →

FAQ

How long has NEXTBio Capital Management LP held STTK?

NEXTBio Capital Management LP has disclosed STTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is NEXTBio Capital Management LP's current position in STTK?

As of Q3 2026, NEXTBio Capital Management LP holds 3.73M shares of STTK (SHATTUCK LABS INC), valued at $25.42M, representing 11.07% of its reported portfolio and ranking #2.

Has NEXTBio Capital Management LP been buying or selling STTK?

In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in STTK. The position peaked in Q2 2026 at 3.73M shares.

Which other funds hold STTK?

Other major institutional holders of STTK include Redmile Group, LLC, ORBIMED ADVISORS LLC, Prosight Management, LP, among 59 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.